ArticleScientific reports2026
Enhanced breast cancer detection framework based on YOLOv11n with multi-scale feature calibration.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A lightweight improved YOLOv11 framework for intracranial hemorrhage detection.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer poses a persistent global health challenge, making early diagnosis indispensable for reducing mortality and improving patient prognosis. However, conventional detection paradigms are frequently impeded by the inherent complexity of lesions, characterized by minute dimensions, morphological heterogeneity, and indistinct boundaries. To address these impediments, this study proposes an advanced detection framework building upon YOLOv11n. We introduce three novel architectural components, specifically the C3k2-DCNv2-Dynamic, C2CGA, and CSFCN modules, designed to synergize feature extraction, fusion, and calibration. The C3k2-DCNv2-Dynamic module employs dynamic convolution and deformable mechanisms to robustly accommodate scale variations. Concurrently, the C2CGA module exploits a channel-guided attention mechanism within a multi-branch topology to heighten sensitivity toward complex lesion regions. Furthermore, the CSFCN module synthesizes contextual and spatial feature calibration to refine the identification of small targets. Extensive empirical evaluations validate the efficacy of the proposed method. The model achieved a precision of 66.6% and a mean Average Precision (mAP@0.5) of 86.2%, surpassing the baseline YOLOv11n by 5.5 and 2.4% points, respectively. Notably, detection accuracy for small G2-class lesions improved by a substantial 14.1% points. These findings substantiate the superior performance of our framework in resolving small and complex lesion detection, suggesting significant potential for clinical deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.